Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check4 days agoChange DetectedThe page now lists a newer site revision label 'Revision: v3.5.4', replacing 'Revision: v3.5.3'. This reflects a deployment update to the ClinicalTrials.gov interface rather than a change to the study information.SummaryDifference0.1%

- Check11 days agoNo Change Detected
- Check19 days agoChange DetectedRevision: v3.5.3 replaces the previous v3.5.2 on the page. This reflects a minor platform update to the study record interface.SummaryDifference0.1%

- Check26 days agoChange DetectedAdded “Type 2 diabetes” related topics, including a MedlinePlus Genetics section.SummaryDifference0.2%

- Check33 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision: v3.5.0 was added and Revision: v3.4.3 was removed.SummaryDifference0.1%

- Check69 days agoChange DetectedMetadata updates include adding the topic 'Type 2 diabetes' and the related topic 'MedlinePlus Genetics', and the site revision updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.